The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells.
Open accessAbstract
The administration of the immunosuppressive humanized monoclonal antibody CAMPATH 1-H, which recognizes CD52 on lymphocytes and monocytes, is associated with a first-dose cytokine-release syndrome involving TNFalpha, IFNgamma, and IL-6 clinically. In vitro models have been used to establish the cellular source and mechanism responsible for cytokine release, demonstrating that cytokine release is isotype dependent, with the rat IgG2b and human IgG1 isotype inducing the highest levels of cytokine release, which was inhibited with antibody to CD16, the low affinity Fc-receptor for IgG (FcgammaR). Cross-linking antibody opsonized CD4 T lymphocytes failed to stimulate TNFalpha release, which together with the observation that TNFalpha release by purified natural killer (NK) cells stimulated by fixed autologous CAMPATH 1-H-opsonized targets was inhibited with anti-CD16, indicates that cytokine release results from ligation of CD16 on the NK cells, rather than Fc-receptor (FcR)-dependent cross-linking of CD52 on the targeted cell. Since the hierarchy of isotypes inducing cytokine release in these cultures matches that seen clinically, we conclude that ligation of CD16 on NK cells is also responsible for cytokine release after injection of CAMPATH 1-H in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It was established that TGN1412 stimulates CD4+ T-cells to undergo lymphoproliferation and release pro-inflammatory cytokines (Stebbings et al., 2007).”
From After TGN1412: Recent developments in cytokine release assays (2013) · cites this paper as Wing et al., 1996
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This mechanism of cytokine release would likely involve engagement of CD16 (FcgammaRIII) on NK cells by the Fc component of immobilized therapeutic mAbs 25 .”
From Severity of the TGN 1412 trial disaster cytokine storm correlated with IL‐2 release (2013) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reshaping human antibodies for therapy
Riechmann, L., Clark, M., Waldmann, H., & Winter, G. P. (1988) · Nature · doi:10.1038/332323a0 · Cited by 1,565
Self-citationOrtho Multicenter Transplant Study Group* (1985) · New England Journal of Medicine · doi:10.1056/nejm198508083130601 · Cited by 720
REMISSION INDUCTION IN NON-HODGKIN LYMPHOMA WITH RESHAPED HUMAN MONOCLONAL ANTIBODY CAMPATH-1H
Hale, G., Clark, M., Marcus, R. E., Winter, G. P., Dyer, M. J. S., Phillips, J. M., Riechmann, L., & Waldmann, H. (1988) · The Lancet · doi:10.1016/s0140-6736(88)90588-0 · Cited by 688
Self-citationHan, J. S., Thompson, P., & Beutler, B. (1990) · The Journal of Experimental Medicine · doi:10.1084/jem.172.1.391 · Cited by 508
Co-association of CD3ζ with a receptor (CD16) for IgG Fc on human natural killer cells
Lanier, L. L., Yu, G., & Phillips, J. H. (1989) · Nature · doi:10.1038/342803a0 · Cited by 436
PERUSSIA, B., Starr, S. E., Abraham, S. R., Fanning, V., & Trinchieri, G. (1983) · The Journal of Immunology · doi:10.4049/jimmunol.130.5.2133 · Cited by 409
TREATMENT OF ACUTE RENAL ALLOGRAFT REJECTION WITH OKT3 MONOCLONAL ANTIBODY
Cosimi, A. B., Burton, R. C., Colvin, R. B., Goldstein, G., Delmonico, F. L., LaQuaglia, M. P., TOLKOFF-RUBIN, N. E., Rubin, R. H., Herrin, J. T., & Russell, P. S. (1981) · Transplantation · doi:10.1097/00007890-198112000-00018 · Cited by 389
Dexamethasone-mediated inhibition of human T cell growth factor and gamma-interferon messenger RNA.
Arya, S. K., Wong‐Staal, F., & Gallo, R. C. (1984) · The Journal of Immunology · doi:10.4049/jimmunol.133.1.273 · Cited by 387
Anegón, I., Cuturi, M. C., Trinchieri, G., & PERUSSIA, B. (1988) · The Journal of Experimental Medicine · doi:10.1084/jem.167.2.452 · Cited by 368
Dyer, M. J. S., Hale, G., Hayhoe, F. G. J., & Waldmann, H. (1989) · Blood · doi:10.1182/blood.v73.6.1431.1431 · Cited by 349
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–257 of 257
Yoo, E. M., & Morrison, S. L. (2009) · Encyclopedia of Industrial Biotechnology · doi:10.1002/9780470054581.eib044 · Cited by 2
The immunological bases of alemtuzumab as induction-therapy in pediatric-onset multiple sclerosis
Puthenparampil, M., Gaggiola, M., Rinaldi, F., Nosadini, M., Sartori, S., Perini, P., & Gallo, P. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1509987 · Cited by 1
Selecting an Optimal Antibody for Antibody–Drug Conjugate Therapy
Ritchie, M. F., Bloom, L., Carven, G. J., & Sapra, P. (2025) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-031-83005-1_3 · Cited by 1
DIET, BACTERIA AND INFLAMMATION: THE INTESTINAL MUCOSA AND METABOLIC SYNDROME
Mohammed, N. (2012) · UKnowledge (University of Kentucky) · Cited by 1
Alemtuzumab to treat multiple sclerosis
Tuohy, O., & Coles, A. J. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9781139023986.035 · Cited by 1
Hamid, F. F. A., Singer, M., El-Rouby, M. N., Said, M. M., Tabashy, R. H., & El-Houseini, M. E. (2018) · Journal of cancer research updates · doi:10.6000/1929-2279.2018.07.01.3 · Cited by 1
Chimeric Antigen Receptor (CAR) T-Cell Therapy in the Pediatric Critical Care
Khazal, S. J., & Mahadeo, K. M. (2019) · Springer eBooks · doi:10.1007/978-3-319-74588-6_200 · Cited by 3
Antibody Fc engineering for optimal antibody performance
(2012) · Elsevier eBooks · doi:10.1533/9781908818096.225 · Cited by 1
Immunotoxicology of Biopharmaceutics
Haggerty, H. G., Price, K. D., & Shenton, J. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-08-100601-6.02008-1 · Cited by 1
Systemic Syndromes with Biomedicines
Tridente, G. (2013) · Springer eBooks · doi:10.1007/978-88-470-5313-7_3 · Cited by 1
Balhorn, R., & Balhorn, M. C. (2020) · Oncotarget · doi:10.18632/oncotarget.27709 · Cited by 1
Yüceyar, N., Dalgıç, C. T., Mete, N., Özışık, M., & Baklan, M. (2021) · Nöro Psikiyatri Arşivi · doi:10.29399/npa.27371 · Cited by 1
Toxicology and Adverse Drug Reactions
Snodin, D. J., & Suitters, A. (2011) · Wiley eBooks · doi:10.1002/9780470975053.ch3 · Cited by 1
An Update on Monoclonal Antibody Therapies in Multiple Sclerosis
Choudry, B. A., & Chan, J. W. (2007) · Journal of Pharmacy Practice · doi:10.1177/0897190007305147 · Cited by 1
20 The Role of Glycosylation in Engineered Antibodies
Morrison, S. L. (2005) · doi:10.1201/9781420027631-21 · Cited by 1
(2012) · Elsevier eBooks · doi:10.1016/b978-1-907568-37-4.50029-4 · Cited by 1
Targeting CD52 for the Treatment of Multiple Sclerosis
Coles, A. J., & Jones, J. (2013) · Springer eBooks · doi:10.1007/978-1-4614-7953-6_18
Targeted monoclonal antibody therapy in chronic lymphocytic leukemia
Karlsson, C. (2010) · Figshare
Profiling Adverse Immune Effects
de Jong, W. H., Pieters, R. H. H., Baken, K. A., Vandebriel, R. J., van der Laan, J. W., & Loveren, H. V. (2009) · Methods and principles in medicinal chemistry · doi:10.1002/9783527627448.ch18
Co‐Administration of Co‐Stimulatory Moieties
Arancibia-Cárcamo, C. V., & Latchman, Y. E. (2012) · Wiley eBooks · doi:10.1002/9781118345313.ch25
Polymorphisms of FcγRIIIa on NK cells and macrophages
Koene, H. R., Borne, A. E. G. K. V. D., Roos, D., & de Haas, M. (1998) · Springer eBooks · doi:10.1007/978-94-011-5018-7_12
Immunotoxicology of Biopharmaceutics
Haggerty, H. G., Price, K., & Shenton, J. M. (2010) · Elsevier eBooks · doi:10.1016/b978-0-08-046884-6.00629-1
Mechanisms of Alemtuzumab-Mediated Cytotoxicity in Hematologic Malignancies
Lin, T. S. (2007) · Clinical Leukemia · doi:10.3816/clk.2007.n.004
Winkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V., & Engert, A. (2016)
Tolerancja i bezpieczeństwo stosowania rituksymabu (MabThera
Kimby, E. K. (2006) · Via Medica Journals
Monoclonal Antibodies (mAb) in the Therapy of T-Cell Lymphomas
Alinari, L., Porcu, P., & Coiffier, B. (2012) · Humana Press eBooks · doi:10.1007/978-1-62703-170-7_14
Malignant LymphomasResearch Paper
Golay, J., Manganini, M., Rambaldi, A., & Introna, M. (2004)
Chronic Lymphocytic Leukemia and Related Chronic Leukemias
Lin, T. S., & Byrd, J. C. (2006) · Springer eBooks · doi:10.1007/0-387-31056-8_65
Killestein, J., & Polman, C. H. (2007) · PubMed
Coles, A. J., Jones, J., & Compston, A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-801914-6.00019-2
Self-citationAnesthesia and Perioperative Care in Reconstructive Transplantation
Planinsic, R. M., Raval, J. S., & Gorantla, V. S. (2017) · Anesthesiology Clinics · doi:10.1016/j.anclin.2017.04.008
Cancer immunotherapy: Adoptive cell therapies, cytokine-related toxicities, and the kidneys
Edeani, A. (2019) · Journal of Onco-Nephrology · doi:10.1177/2399369319863433
Writers, A. M. (2019) · Drugs & Therapy Perspectives · doi:10.1007/s40267-019-00693-x
(2011) · Springer eBooks · doi:10.1007/springerreference_38111
Li, Q., Deng, H., Liu, M.-C., Lyu, C., Zhu, H., Wang, J., Jiang, Y., Pu, Y. D., Jiang, Y. Y., Li, W., et al. (2021) · Europe PMC (PubMed Central) · doi:10.3760/cma.j.issn.0253-2727.2021.07.007
Colinot, A., & Maréchal, N. (2011) · Forêt entreprise
Cartwright, M. E. (2021) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.740082890.793585479
(2006) · Elsevier eBooks · doi:10.1016/b978-0-443-07271-0.50022-7
Goodman, A. M., Tanaka, T. N., & Kaufman, D. S. (2017) · Current cancer research · doi:10.1007/978-3-319-63757-0_5
Parker, G. A., & Papenfuss, T. L. (2017) · Molecular and integrative toxicology · doi:10.1007/978-3-319-47377-2_1
Immunotoxicology of Biopharmaceutics☆
Haggerty, H. G., Price, K., & Shenton, J. M. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.02008-0
Field, M. C. (2002) · Wiley Encyclopedia of Molecular Medicine · doi:10.1002/0471203076.emm0159
General Toxicity Testing and Immunotoxicity Testing for Biopharmaceuticals
Bussiere, J. L. (2010) · Pharmaceutical Sciences Encyclopedia · doi:10.1002/9780470571224.pse175
MacLeod, E., Rajagopal, D., & Vessillier, S. (2023) · Journal of Visualized Experiments · doi:10.3791/65087
MacLeod, E., Rajagopal, D., & Vessillier, S. (2023) · doi:10.3791/65087-v
Kaufman, D. B., Felix, D. C., & Little, C. J. (2023) · Springer eBooks · doi:10.1007/978-3-031-20999-4_48
The Development, Indications, and the Safety of Monoclonal Antibodies
Güney, H. Z. (2023) · Lokman Hekim Health Sciences · doi:10.14744/lhhs.2023.12008
Bergua, C., Ahmil, G., Ouisse, L., Vimond, N., Sérazin, C., Dugast, L., Humeau, R., Salama, A., Tesson, L., Swinnen, K., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.10.057
Immunotoxicology of Biopharmaceutics
Haggerty, H. G., Price, K., & Shenton, J. M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-95488-4.50043-6
A phase 1 experimental medicine study of anti-CD3 monoclonal antibody in rheumatoid arthritis
Lawson, C., Harry, R. A., Griffiths, B., Hale, G., Waldmann, H., & Isaacs, J. D. (2024) · Immunotherapy Advances · doi:10.1093/immadv/ltaf034
Self-citationRajagopal, D., Ieong, K. S., Mate, R., & Vessillier, S. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1736130
Le rôle de GDF11 dans les leucémies aiguës myéloïdes
Siavellis, J. (2021) · theses.fr (ABES) · doi:10.70675/b953e730zc0bez4347za9e4z561daebbcc2d
Sierocki, R. (2020) · theses.fr (ABES) · doi:10.70675/a21eef57z41b9z4748z9da6z2af2b38799d6
Immune Effector Cell and Gene Therapies in Pediatric Critical Care
Ragoonanan, D. S., & Mahadeo, K. M. (2026) · Springer eBooks · doi:10.1007/978-3-319-74698-2_200-2
Clinical trials of multiple sclerosis therapies
Cohen, J. A., & Rudick, R. A. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9781139023986.028
Immunotoxin Therapy of Chronic Lymphocytic Leukemia
Frankel, A. E., & Kreitman, R. J. (2004) · Humana Press eBooks · doi:10.1007/978-1-59259-412-2_16
Metadata
- Authors
- Wing, M. G., Moreau, T., Greenwood, J., Smith, R. M., Hale, G., Isaacs, J., Waldmann, H., Lachmann, P. J., & Compston, A.
- Affiliations
- Medical Research Council (GB)
- University of Cambridge (GB)
- University of Oxford (GB)
- Venue
- Journal of Clinical Investigation
- Published
- 1996-12-15
- Volume
- 98
- Issue
- 12
- Pages
- 2819-2826
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC507749
- OpenAlex
- W2069219892
- Cited by
- 257
- References
- 43
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 8 · 2023: 5 · 2022: 5 · 2021: 11 · 2020: 12 · 2019: 15 · 2018: 11 · 2017: 11 · 2016: 11 · 2015: 7 · 2014: 8 · 2013: 12 · 2012: 8
- FWCI
- 1.37
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust
- Medical Research Council
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Keywords
- cytokine release syndrome, CD52, natural killer cells, CD16, Fc gamma receptor I, LFA-1, CD11a/CD18, antibody isotypes, TNF-α, interferon-gamma, interleukin-6
- MeSH terms
- Alemtuzumab, Antibodies, Monoclonal, Antibodies, Neoplasm, Enzyme-Linked Immunosorbent Assay, Humans, Immunoglobulin G, Immunoglobulin M, Interferon-gamma, Killer Cells, Natural, Leukocytes, Tumor Necrosis Factor-alpha, CD4-Positive T-Lymphocytes, Interleukin-6, Cytokines, Receptors, IgG, CD11 Antigens, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
